67 related articles for article (PubMed ID: 5656771)
1. A record of accomplishment.
Provost GP
Am J Hosp Pharm; 1968 Jun; 25(6):269. PubMed ID: 5656771
[No Abstract] [Full Text] [Related]
2. Retrospective view of the interfacial relationship of the pharmaceutical industry with the Food and Drug Administration and the United States Pharmacopeia.
Hammer HF
J Parenter Sci Technol; 1984; 38(4):159-63. PubMed ID: 6491859
[No Abstract] [Full Text] [Related]
3. Setting the record straight on PDR criticisms.
Mehta M
Postgrad Med; 2000 Jan; 107(1):22. PubMed ID: 10649658
[No Abstract] [Full Text] [Related]
4. Manufacturing misdeeds cost Abbott record-breaking payment.
Lewis C
FDA Consum; 2000; 34(3):38-9. PubMed ID: 11521253
[No Abstract] [Full Text] [Related]
5. [Problems connected with the drug provision in the United States].
Sloot HA
Pharm Weekbl; 1969 Jul; 104(30):914-23. PubMed ID: 5800761
[No Abstract] [Full Text] [Related]
6. Biopharmaceutic equivalency and the role of the Food & Drug Administration.
Hodges RM
Am J Hosp Pharm; 1968 Mar; 25(3):121-7. PubMed ID: 5658859
[No Abstract] [Full Text] [Related]
7. The Food and Drug Administration drug registration and listing system.
Slavin M
Drug Inf J; 1975; 9(2-3):239-40. PubMed ID: 10236978
[No Abstract] [Full Text] [Related]
8. Personal responsibility and the Food and Drug Law.
Janssen WF
FDA Consum; 1975 Nov; 9(9):10-3. PubMed ID: 10308122
[No Abstract] [Full Text] [Related]
9. Knowledge is power: legislative control of drug industry trade secrets.
O'Reilly JT
Spec Law Dig Health Care (Mon); 1987 May; 8(15):7-31. PubMed ID: 10281981
[No Abstract] [Full Text] [Related]
10. The United States Food and Drug Administration and the end of antibiotics.
Shlaes DM; Moellering RC
Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
[No Abstract] [Full Text] [Related]
11. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
Zelenay JL
Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
[No Abstract] [Full Text] [Related]
12. [Quo vadis medicina? 15. Drug trials in the United States today].
Müller-Ehrenberg KH
Hippokrates; 1968 Feb; 39(3):105-7. PubMed ID: 5721794
[No Abstract] [Full Text] [Related]
13. A strike against preemption.
Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
[TBL] [Abstract][Full Text] [Related]
14. The parenteral drug industry: recent findings.
Fry EM
J Parenter Sci Technol; 1982; 36(2):55-8. PubMed ID: 7077464
[No Abstract] [Full Text] [Related]
15. Remarks by the Commissioner of Food and Drugs.
Kessler DA
Food Drug Law J; 1995; 50(2):327-34. PubMed ID: 10343001
[No Abstract] [Full Text] [Related]
16. Regulated firms: a statistical profile.
Hecht A
FDA Consum; 1977 Apr; 11(3):24. PubMed ID: 10304990
[No Abstract] [Full Text] [Related]
17. View from the Nation's Capital.
Romansky MA
J Clin Psychopharmacol; 1984 Jun; 4(3):161-2. PubMed ID: 6096408
[No Abstract] [Full Text] [Related]
18. FDA-industry relations: progress from confrontation to communication.
Robinson JR
J Parenter Sci Technol; 1983; 37(4):111-2. PubMed ID: 6620041
[No Abstract] [Full Text] [Related]
19. Interaction among government, industry, and extramural investigators: new developments and problems.
Psychopharmacol Bull; 1982 Jul; 18(3):64-70. PubMed ID: 7146254
[No Abstract] [Full Text] [Related]
20. Conflict of interest in industry-sponsored drug development.
Emanuel EJ
Clin Adv Hematol Oncol; 2007 Apr; 5(4):265-7. PubMed ID: 17607285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
